27638646|t|Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories
27638646|a|There is a great need for improved diagnostic and prognostic accuracy of potential cardiac toxicity in drug development. This study reports the evaluation of several commercially available biomarker kits by 3 institutions (SRI, Eli Lilly, and Pfizer) for the discrimination between myocardial degeneration / necrosis and cardiac hypertrophy as well as the assessment of the interlaboratory and interplatform variation in results. Serum concentrations of natriuretic peptides (N-terminal pro-atrial natriuretic peptide [NT-proANP] and N-terminal pro-brain natriuretic peptide [NT-proBNP]), cardiac and skeletal troponins (cTnI, cTnT, and sTnI), myosin light chain 3 (Myl3), and fatty acid binding protein 3 (FABP3) were assessed in rats treated with minoxidil (MNX) and isoproterenol (ISO). MNX caused increased heart -to- body weight ratios and prominent elevations in NT-proANP and NT-proBNP concentrations detected at 24-hr postdose without elevation in troponins, Myl3, or FABP3 and with no abnormal histopathological findings. ISO caused ventricular leukocyte infiltration, myocyte fibrosis, and necrosis with increased concentrations of the natriuretic peptides, cardiac troponins, and Myl3. These results reinforce the advantages of a multimarker strategy in elucidating the underlying cause of cardiac insult and detecting myocardial tissue damage at 24-hr posttreatment. The interlaboratory and interplatform comparison analyses also showed that the data obtained from different laboratories and platforms are highly correlated and reproducible, making these biomarkers widely applicable in preclinical studies.
27638646	14	30	Cardiac Toxicity	T037	UMLS:C0876994
27638646	31	41	Biomarkers	T201	UMLS:C0005516
27638646	45	49	Rats	T204	UMLS:C0034693
27638646	65	77	Laboratories	T092	UMLS:C0022877
27638646	104	112	improved	T033	UMLS:C0184511
27638646	128	138	prognostic	T170	UMLS:C0220901
27638646	161	177	cardiac toxicity	T037	UMLS:C0876994
27638646	181	197	drug development	T091	UMLS:C0872152
27638646	204	209	study	T062	UMLS:C2603343
27638646	210	217	reports	T062	UMLS:C0011000
27638646	267	281	biomarker kits	T201	UMLS:C0005516
27638646	287	299	institutions	T092	UMLS:C2607850
27638646	301	304	SRI	T092	UMLS:C2607850
27638646	360	383	myocardial degeneration	T038	UMLS:C0027046
27638646	386	394	necrosis	T038	UMLS:C1442837
27638646	399	418	cardiac hypertrophy	T038	UMLS:C1383860
27638646	532	552	natriuretic peptides	T103	UMLS:C1144709
27638646	554	595	N-terminal pro-atrial natriuretic peptide	T103	UMLS:C0027481
27638646	597	606	NT-proANP	T103	UMLS:C0027481
27638646	612	652	N-terminal pro-brain natriuretic peptide	T103	UMLS:C0754710
27638646	654	663	NT-proBNP	T103	UMLS:C0754710
27638646	667	674	cardiac	T017	UMLS:C0018787
27638646	679	687	skeletal	T082	UMLS:C0521324
27638646	688	697	troponins	T103	UMLS:C0041199
27638646	699	703	cTnI	T103	UMLS:C1305957
27638646	705	709	cTnT	T103	UMLS:C3538889
27638646	715	719	sTnI	T103	UMLS:C0033684
27638646	722	742	myosin light chain 3	T103	UMLS:C0027108
27638646	744	748	Myl3	T103	UMLS:C0027108
27638646	755	783	fatty acid binding protein 3	T103	UMLS:C1721418
27638646	785	790	FABP3	T103	UMLS:C1721418
27638646	809	813	rats	T204	UMLS:C0034693
27638646	827	836	minoxidil	T103	UMLS:C0026196
27638646	838	841	MNX	T103	UMLS:C0026196
27638646	847	860	isoproterenol	T103	UMLS:C0022245
27638646	862	865	ISO	T103	UMLS:C0022245
27638646	868	871	MNX	T103	UMLS:C0026196
27638646	889	894	heart	T017	UMLS:C0018787
27638646	933	943	elevations	T082	UMLS:C0702240
27638646	947	956	NT-proANP	T103	UMLS:C0027481
27638646	961	970	NT-proBNP	T103	UMLS:C0754710
27638646	986	994	detected	T033	UMLS:C0442726
27638646	1021	1030	elevation	T082	UMLS:C0702240
27638646	1034	1043	troponins	T103	UMLS:C0041199
27638646	1045	1049	Myl3	T103	UMLS:C0027108
27638646	1054	1059	FABP3	T103	UMLS:C1721418
27638646	1069	1071	no	T033	UMLS:C1513916
27638646	1072	1080	abnormal	T033	UMLS:C0205161
27638646	1099	1107	findings	T033	UMLS:C0243095
27638646	1109	1112	ISO	T103	UMLS:C0022245
27638646	1120	1131	ventricular	T082	UMLS:C1522565
27638646	1132	1154	leukocyte infiltration	T033	UMLS:C0333361
27638646	1156	1172	myocyte fibrosis	T038	UMLS:C0151654
27638646	1178	1186	necrosis	T038	UMLS:C0027540
27638646	1224	1244	natriuretic peptides	T103	UMLS:C1144709
27638646	1246	1253	cardiac	T017	UMLS:C0018787
27638646	1254	1263	troponins	T103	UMLS:C0041199
27638646	1269	1273	Myl3	T103	UMLS:C0027108
27638646	1379	1393	cardiac insult	T038	UMLS:C0018799
27638646	1398	1407	detecting	T033	UMLS:C0442726
27638646	1408	1418	myocardial	T017	UMLS:C0027061
27638646	1419	1432	tissue damage	T037	UMLS:C0010957
27638646	1506	1514	analyses	T062	UMLS:C0936012
27638646	1565	1577	laboratories	T092	UMLS:C0022877
27638646	1645	1655	biomarkers	T201	UMLS:C0005516
27638646	1677	1696	preclinical studies	T062	UMLS:C1709631